NGD 944
Latest Information Update: 19 Sep 1997
At a glance
- Originator Neurogen Corporation
- Developer Schering-Plough
- Class Antipsychotics
- Mechanism of Action Dopamine D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 19 Sep 1997 Discontinued-I for Schizophrenia in United Kingdom (Unknown route)
- 02 Jul 1997 New profile